迪戈辛可以通过TNF/NF-κB和LRP4信号传递来防止椎间盘退化
Qunbo Meng1,2, Kaiwen Liu1,2, Zhenchuan Liu1,2
1Department of Orthopaedic Surgery, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Frontiers in immunology
|October 4, 2023
概括
迪戈辛在治疗椎间盘退化 (IVDD) 方面表现有前途,通过减少炎症和促进细胞外矩阵 (ECM) 修复. 这项研究确定了LRP4作为狄戈辛的关键分子标.
科学领域:
- 生物医学科学 生物医学科学
- 分子生物学分子生物学
- 再生医学是一种再生医学.
背景情况:
- 椎间盘退化 (IVDD) 是腰部疼痛的主要原因,其特征是炎症和细胞外基质 (ECM) 干扰.
- 迪戈辛是一种心力衰竭药物,具有已知的抗炎性质.
- 了解狄戈辛在IVDD发病过程中的作用,对于开发新的治疗策略至关重要.
研究的目的:
- 研究狄戈辛在椎间盘退化 (IVDD) 的治疗潜力.
- 阐明底层的分子机制 狄戈辛对IVDD的影响.
- 在IVDD的背景下,确定狄戈辛的特定蛋白标.
主要方法:
- 在IVDD研究中使用了老鼠针模型.
- 采用SAFRANIN O和HEMATOXYLIN-EOSIN (H&E) 染色用于组织学分析.
- 通过Western Blot,实时PCR,免疫光和免疫化学,研究了迪戈辛对细胞核脉 (NP) 体外 的作用.
- 评估了低密度脂蛋白受体相关蛋白4 (LRP4) 作为通过siRNA介导的敲击来作为潜在的迪戈辛标的作用.
主要成果:
- 迪戈辛在动物模型中显示出对IVDD的保护作用.
- 迪戈辛抑制了TNF-α诱导的炎症,并减弱了ECM的破坏.
- 迪戈辛显著促进了ECM类 anabolism,而LRP4被确定为一个关键的下游媒介.
- 降低LRP4降低了NP细胞中狄戈辛的保护作用.
结论:
- 迪戈辛通过促进合成体和减少合成体,显示出作为IVDD治疗剂的潜力.
- 迪戈辛的机制涉及LRP4信号通路的调节.
- 迪戈辛可能为除了心血管疾病之外的与炎症相关的疾病提供一种新的治疗方法.
相关概念视频
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
698
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
698
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Rheumatic Heart Disease IV: Nursing Management
18
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
18


